Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 158.00 GBp
Change Today +1.50 / 0.96%
Volume 68.0K
HZD On Other Exchanges
As of 11:39 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

horizon discovery group plc (HZD) Snapshot

156.50 GBp
Previous Close
156.50 GBp
Day High
158.50 GBp
Day Low
156.50 GBp
52 Week High
01/19/15 - 236.00 GBp
52 Week Low
11/12/14 - 146.50 GBp
Market Cap
Average Volume 10 Days
-0.09 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

horizon discovery group plc (HZD) Related Businessweek News

No Related Businessweek News Found

horizon discovery group plc (HZD) Details

Horizon Discovery Group plc, a life science company, supplies products, services, and research programs to organizations in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops genetically defined cell lines using its GENESIS platform that model the disease-causing mutations found in patients with cancer and other diseases. The company also provides short hairpin ribonucleic acid and over expression reagents; off the shelf cell lines; reporter kits; genome editing tools; next-generation in vivo research models and support services under the SAGE product brand; and genetically defined human genomic reference standards, including formalin-fixed paraffin embedded tissue cell line sections and purified genomic deoxyribonucleic acid. In addition, it offers bioproduction cell lines; in-vitro and in-vivo assay development and drug screening services in various areas, such as cell growth, signal transduction, apoptosis, angiogenesis, and metastasis; and ribonucleic acid-based screening, drug combination screening, custom cell line and animal model development, and transgenic support services. Further, the company provides unique cHTS platform and Chalice analytics software, which enables the screening and analysis of various complementary drug combinations. It serves pharmaceutical, biotech, and diagnostic companies, as well as academic research centres. The company was founded in 2005 and is based in Cambridge, the United Kingdom.

183 Employees
Last Reported Date: 05/26/15
Founded in 2005

horizon discovery group plc (HZD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: 397.3K GBP
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: --
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: 265.3K GBP
Chief Business Officer and Executive Director
Total Annual Compensation: 61.2K GBP
Compensation as of Fiscal Year 2014.

horizon discovery group plc (HZD) Key Developments

Horizon Discovery Group plc Reports Sales Results for the Six Months Ended June 30, 2014

Horizon Discovery Group plc reported sales results for the six months ended June 30, 2014. For the period, the Group reported revenues of £8.6 million, 112% ahead of the equivalent period in the prior year in six months to June 30, 2014 of £4.1 million.

Horizon Discovery Mulls Acquisitions

Horizon Discovery Group plc (AIM:HZD) is looking for acquisitions. Chief Executive Darrin Disley, a former West Ham United youth player, said that Horizon Discovery would look to accelerate growth by making more acquisitions.

Horizon Discovery Group plc and Definigen Ltd Announce Collaboration to Develop Gene-Engineered iPS-Based Cell Lines

Horizon Discovery Group plc and Definigen Ltd. announced their collaboration to develop a range of unique, gene-engineered iPS (induced pluripotent stem)-based cell lines for use in research. Under the terms of the agreement, Horizon will perform genome engineering on the iPS cells, which will then be differentiated by DefiniGEN. The project will initially focus on generation of ten iPS-based cell lines for research in areas that currently lack high quality disease models. The resulting cell lines will be cultured, differentiated and quality controlled by DefiniGEN to ensure that scientists receive uniform cell populations suited to their experiments, alongside an isogenic control. The cell line reagents will be available through DefiniGEN and co-marketed by Horizon. The partnership, formed to enable customers to exploit the power of genome editing in iPS cells, is made possible through Horizon’s deep expertise in gene editing, and DefiniGEN’s iPS cell-derived human cell production and metabolic disease modeling capabilities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZD:LN 158.00 GBp +1.50

HZD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HZD.
View Industry Companies

Industry Analysis


Industry Average

Valuation HZD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.7x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON DISCOVERY GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at